GPX2 and urothelial carcinoma: GPX2 positivity was most seen in colorectal adenocarcinomas (97.9%) and adenomas (100%), non-invasive urothelial carcinomas (88.9-100%), pancreatico-biliary cancers (83.4-94.7%), Brenner tumors of the ovary (89.7%), gastro-esophageal adenocarcinomas (83.1-87.3%), and seminomas (85.6%).